orforglipron

Lilly Eyes 2025 Approval for Obesity Pill as Pivotal Phase 3 Trial Approaches

Eli Lilly’s orforglipron, a once-daily oral weight-loss pill, is set to enter a pivotal Phase 3 trial in non-diabetic obese…

Read More »